InvestorsHub Logo
Followers 22
Posts 999
Boards Moderated 0
Alias Born 07/23/2017

Re: misiu143 post# 45

Tuesday, 10/16/2018 7:20:22 AM

Tuesday, October 16, 2018 7:20:22 AM

Post# of 82
Although you only need one indication to catch the eyes of big Pharma Bit225 has 2 applications. HCV and HIV. Plus BITRF has other compounds. If buy out occurs or partnering it will be to swilling up there entire portfolio of compounds. For example Gillead bought one compound for $11.4 billion after a phase 2 trial in past. Not even sure the drug ever commercialized. BITRF is a keeper until commercialization or buy out occurs